{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:33:30Z","timestamp":1792596810665,"version":"4.5.0"},"reference-count":130,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service","award":["DK56338"],"award-info":[{"award-number":["DK56338"]}]},{"name":"Public Health Service","award":["5T32DK083266-07"],"award-info":[{"award-number":["5T32DK083266-07"]}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.cgh.2017.09.033","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T15:46:16Z","timestamp":1506613576000},"page":"800-808.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":184,"title":["Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6908-8317","authenticated-orcid":false,"given":"David Y.","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Tansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2017.09.033_bib1","doi-asserted-by":"crossref","first-page":"e56060","DOI":"10.1371\/journal.pone.0056060","article-title":"Proton pump inhibitor use in the U.S. ambulatory setting, 2002-2009","volume":"8","author":"Rotman","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2017.09.033_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/1756283X16650156","article-title":"Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study","volume":"9","author":"Pottegard","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib3","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jamainternmed.2014.2900","article-title":"National use of proton pump inhibitors from 2007 to 2011","volume":"174","author":"Johansen","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cgh.2017.09.033_bib4","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1136\/gut.28.9.1120","article-title":"Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs","volume":"28","author":"Jones","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2017.09.033_bib5","doi-asserted-by":"crossref","first-page":"24S","DOI":"10.1007\/BF02214870","article-title":"Optimizing acid suppression for treatment of acid-related diseases","volume":"40","author":"Hunt","year":"1995","journal-title":"Dig Dis Sci"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2017.09.033_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000200917","article-title":"Appropriate acid suppression for the management of gastro-oesophageal reflux disease","volume":"51","author":"Bell","year":"1992","journal-title":"Digestion"},{"key":"10.1016\/j.cgh.2017.09.033_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/00365529409105369","article-title":"Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease","volume":"201","author":"Howden","year":"1994","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.cgh.2017.09.033_bib8","first-page":"159","article-title":"pH, healing rate and symptom relief in acid-related diseases","volume":"69","author":"Huang","year":"1996","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.cgh.2017.09.033_bib9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archinte.159.7.649","article-title":"Importance of pH control in the management of GERD","volume":"159","author":"Hunt","year":"1999","journal-title":"Arch Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2017.09.033_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2036.17.s1.2.x","article-title":"Review article: pharmacology of esomeprazole and comparisons with omeprazole","volume":"17","author":"Dent","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2017.09.033_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2036.17.s1.3.x","article-title":"Review article: gastric acidity\u2013comparison of esomeprazole with other proton pump inhibitors","volume":"17","author":"Hatlebakk","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2017.09.033_bib12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2036.17.s1.4.x","article-title":"Review article: initial therapy of reflux disease with esomeprazole","volume":"17","author":"Dent","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00044011-200424010-00001","article-title":"Esomeprazole 20mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers","volume":"24","author":"Rohss","year":"2004","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cgh.2017.09.033_bib14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00228-004-0804-6","article-title":"Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms","volume":"60","author":"Rohss","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cgh.2017.09.033_bib15","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1046\/j.1365-2036.2003.01562.x","article-title":"Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use","volume":"17","author":"Klok","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1155\/2005\/836030","article-title":"Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004","volume":"19","author":"Armstrong","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00228-008-0576-5","article-title":"Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH","volume":"65","author":"Kirchheiner","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cgh.2017.09.033_bib18","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/BF01537242","article-title":"Antimony electrodes. Mucosal potential differences and buffer composition adversely affect pH measurements in the stomach","volume":"35","author":"Opekun","year":"1990","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2017.09.033_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0016-5085(52)80068-X","article-title":"Factors influencing the continuous recording of in situ pH of gastric and duodenal contents","volume":"20","author":"Rovelstad","year":"1952","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.09.033_bib20","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/gut.28.8.935","article-title":"Electrodes for 24 hours pH monitoring\u2013a comparative study","volume":"28","author":"McLauchlan","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2017.09.033_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00042737-199702000-00017","article-title":"Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mg","volume":"9","author":"Florent","year":"1997","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.09.033_bib22","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1046\/j.1365-2036.2002.01292.x","article-title":"Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects","volume":"16","author":"Warrington","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1046\/j.1365-2036.2002.01232.x","article-title":"Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers","volume":"16","author":"Tutuian","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib24","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1023\/A:1018827003641","article-title":"Effect of omeprazole 40 mg once daily on intraduodenal and intragastric pH in H.\u00a0pylori-negative healthy subjects","volume":"42","author":"Gan","year":"1997","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2017.09.033_bib25","first-page":"915","article-title":"Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects","volume":"8","author":"Koop","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.09.033_bib26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2036.1992.tb00057.x","article-title":"The effects of lansoprazole, a new H+,K(+)-ATPase inhibitor, on gastric pH and serum gastrin","volume":"6","author":"Sanders","year":"1992","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/00365520601075845","article-title":"Acid control with esomeprazole and lansoprazole: a comparative dose-response study","volume":"42","author":"Wilder-Smith","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1365-2036.1998.00418.x","article-title":"A\u00a0placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects","volume":"12","author":"Williams","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0016-5085(78)90352-9","article-title":"Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage","volume":"74","author":"Green","year":"1978","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.09.033_bib30","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/17474124.2016.1230496","article-title":"Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis","volume":"10","author":"Oldfield","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.09.033_bib31","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1185\/03007990802693883","article-title":"Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials","volume":"25","author":"Vakily","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cgh.2017.09.033_bib32","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1177\/1756283X16670073","article-title":"Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole","volume":"9","author":"Kukulka","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib33","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/j.1365-2036.2010.04272.x","article-title":"The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a dual delayed release proton pump inhibitor","volume":"31","author":"Lee","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib34","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s12325-016-0345-2","article-title":"Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate (TAK-438)","volume":"33","author":"Otake","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib35","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/apt.13325","article-title":"Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2013a randomised open-label cross-over study","volume":"42","author":"Sakurai","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib36","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/apt.13331","article-title":"Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis","volume":"42","author":"Ashida","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib37","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1185\/03007995.2014.980500","article-title":"Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: a post hoc analysis of the LOTUS trial","volume":"31","author":"Lundell","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cgh.2017.09.033_bib39","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/gut.31.5.509","article-title":"Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring","volume":"31","author":"Dehn","year":"1990","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2017.09.033_bib40","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2009.556","article-title":"Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system","volume":"105","author":"Vasiliadis","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib41","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1046\/j.1365-2036.2001.01030.x","article-title":"Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole","volume":"15","author":"Galmiche","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib42","first-page":"791","article-title":"Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease","volume":"15","author":"Simon","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.09.033_bib43","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/00365529850172304","article-title":"Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease","volume":"33","author":"Janczewska","year":"1998","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib44","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/apt.12301","article-title":"Reflux episodes detected by impedance in patients on and off esomeprazole: a randomised double-blinded placebo-controlled crossover study","volume":"37","author":"Moawad","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib45","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/j.1365-2036.2010.04469.x","article-title":"The effects of dose and timing of esomeprazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers","volume":"32","author":"Wilder-Smith","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib46","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.cgh.2006.09.013","article-title":"Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials","volume":"4","author":"Gralnek","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.09.033_bib47","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","article-title":"Effective and safe proton pump inhibitor therapy in acid-related diseases - a position paper addressing benefits and potential harms of acid suppression","volume":"14","author":"Scarpignato","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.cgh.2017.09.033_bib48","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/BF01297475","article-title":"Antimony electrodes for in\u00a0vivo pH monitoring","volume":"36","author":"Opekun","year":"1991","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2017.09.033_bib49","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/BF01537242","article-title":"Antimony electrodes. Mucosal potential differences and buffer composition adversely affect pH measurements in the stomach","volume":"35","author":"Opekun","year":"1990","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2017.09.033_bib50","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0016-5085(52)80068-X","article-title":"Factors influencing the continuous recording of in situ pH of gastric and duodenal contents","volume":"20","author":"Rovelstad","year":"1952","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.09.033_bib51","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/gut.28.8.935","article-title":"Electrodes for 24 hours pH monitoring\u2013a comparative study","volume":"28","author":"McLauchlan","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2017.09.033_bib52","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/gut.30.5.573","article-title":"Comparison of gastric body and antral pH: a 24 hour ambulatory study in healthy volunteers","volume":"30","author":"McLauchlan","year":"1989","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2017.09.033_bib53","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1046\/j.1365-2036.1998.00416.x","article-title":"Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer","volume":"12","author":"Savarino","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib54","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2036.2006.02787.x","article-title":"The effects of changing temperature correction factors on measures of acidity calculated from gastric and oesophageal pH recordings","volume":"23","author":"Gardner","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib55","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/00365520601075845","article-title":"Acid control with esomeprazole and lansoprazole: a comparative dose-response study","volume":"42","author":"Wilder-Smith","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib56","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00044011-200828060-00001","article-title":"Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study","volume":"28","author":"Wilder-Smith","year":"2008","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cgh.2017.09.033_bib57","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2036.2010.04544.x","article-title":"Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping","volume":"33","author":"Miehlke","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00044011-200424010-00001","article-title":"Esomeprazole 20mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers","volume":"24","author":"Rohss","year":"2004","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cgh.2017.09.033_bib59","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2036.2006.03221.x","article-title":"Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers","volume":"25","author":"Norris","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib60","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1046\/j.1365-2036.2002.01292.x","article-title":"Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects","volume":"16","author":"Warrington","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib61","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2036.2004.01893.x","article-title":"Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers","volume":"19","author":"Galmiche","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib62","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00228-004-0804-6","article-title":"Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms","volume":"60","author":"Rohss","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cgh.2017.09.033_bib63","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1572-0241.2003.08783.x","article-title":"Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study","volume":"98","author":"Miner","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib64","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1046\/j.1365-2036.2003.01743.x","article-title":"Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects","volume":"18","author":"Armstrong","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib65","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2036.2005.02534.x","article-title":"A\u00a0comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease","volume":"22","author":"Johnson","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib66","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000075697","article-title":"Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers","volume":"68","author":"Wilder-Smith","year":"2003","journal-title":"Digestion"},{"key":"10.1016\/j.cgh.2017.09.033_bib67","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1111\/j.1572-0241.2005.41956.x","article-title":"Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers","volume":"100","author":"Hunt","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib68","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2036.2009.04219.x","article-title":"The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects","volume":"31","author":"Hunt","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib69","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1365-2036.2011.04580.x","article-title":"An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers","volume":"33","author":"Morelli","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib70","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2036.2009.04032.x","article-title":"Clinical trial: intragastric acid control in patients who have Barrett's oesophagus\u2013comparison of once- and twice-daily regimens of esomeprazole and lansoprazole","volume":"30","author":"Spechler","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib71","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1365-2036.2004.01949.x","article-title":"Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough","volume":"19","author":"Hammer","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib72","doi-asserted-by":"crossref","first-page":"408","DOI":"10.5152\/tjg.2016.15514","article-title":"Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease","volume":"27","author":"Celebi","year":"2016","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib73","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1023\/A:1015009300955","article-title":"Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease","volume":"47","author":"Rohss","year":"2002","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2017.09.033_bib74","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.clinthera.2006.05.001","article-title":"Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg\/d to 5-day treatment with oral esomeprazole 40 mg\/d or pantoprazole 40 mg\/d: an open-label crossover study in healthy adult volunteers","volume":"28","author":"Miner","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib75","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2036.2009.04150.x","article-title":"A\u00a0comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism","volume":"31","author":"Hunfeld","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib76","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1365-2036.2006.02867.x","article-title":"Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole","volume":"23","author":"Goldstein","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib77","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2036.2010.04335.x","article-title":"Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole","volume":"32","author":"Morgan","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib78","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1046\/j.1365-2036.2002.01232.x","article-title":"Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers","volume":"16","author":"Tutuian","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib79","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/j.1365-2036.2010.04258.x","article-title":"Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors","volume":"31","author":"Miner","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib80","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0149-2918(97)80053-7","article-title":"The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion","volume":"19","author":"Blum","year":"1997","journal-title":"Clin Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib81","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1572-0241.2002.05666.x","article-title":"Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis","volume":"97","author":"Baldi","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib82","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2036.1993.tb00089.x","article-title":"The effects of lansoprazole, 30 or 60 mg daily, on intragastric pH and on endocrine function in healthy volunteers","volume":"7","author":"Dammann","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib83","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2036.1994.tb00293.x","article-title":"Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers","volume":"8","author":"Bruley","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib84","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/003655299750025994","article-title":"Effect of 7-day therapy with different doses of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects","volume":"34","author":"Harder","year":"1999","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib85","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1365-2036.2001.00831.x","article-title":"Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers","volume":"15","author":"Bell","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib86","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2036.1998.00304.x","article-title":"Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects","volume":"12","author":"Geus","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib87","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/MCG.0b013e31818a386e","article-title":"Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD","volume":"43","author":"Howden","year":"2009","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib88","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00042737-199702000-00017","article-title":"Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mg","volume":"9","author":"Florent","year":"1997","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.09.033_bib89","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1365-2036.1998.00306.x","article-title":"Dose-response relationship of lansoprazole to gastric acid antisecretory effects","volume":"12","author":"Blum","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib90","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1365-2036.2002.01168.x","article-title":"Acid suppression in healthy subjects following lansoprazole or pantoprazole","volume":"16","author":"Huang","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib91","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1365-2036.2004.02176.x","article-title":"Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects","volume":"20","author":"Bruley","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib92","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1046\/j.1365-2036.1997.00182.x","article-title":"Twenty-four-hour intragastric acidity and plasma gastrin during 3-month treatment with omeprazole in healthy subjects","volume":"11","author":"Delchier","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib93","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2982.2012.01884.x","article-title":"The effect of once daily omeprazole and succinic acid (VECAM) vs once daily omeprazole on 24-h intragastric pH","volume":"24","author":"Chowers","year":"2012","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2017.09.033_bib94","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1365-2036.1998.00418.x","article-title":"A\u00a0placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects","volume":"12","author":"Williams","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib95","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2036.1995.tb00434.x","article-title":"Twenty-four-hour intragastric acidity: 300 mg ranitidine b.d., 20 mg omeprazole o.m., 40 mg omeprazole o.m. vs. placebo","volume":"9","author":"Houben","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib96","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2036.2006.03129.x","article-title":"Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment","volume":"25","author":"Miner","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib97","first-page":"1532","article-title":"Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls","volume":"91","author":"Kuo","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib98","first-page":"915","article-title":"Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects","volume":"8","author":"Koop","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.09.033_bib99","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1046\/j.1365-2036.1998.00406.x","article-title":"Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole","volume":"12","author":"Hartmann","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib100","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1046\/j.1365-2036.2000.00806.x","article-title":"Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects","volume":"14","author":"Geus","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib101","first-page":"225","article-title":"The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study","volume":"15","author":"Toruner","year":"2004","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib102","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1007\/s10620-010-1176-7","article-title":"Acid control cannot be improved with a modified-release formulation of a proton pump inhibitor compared with twice-daily dosing of the conventional formulation","volume":"55","author":"Rohss","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2017.09.033_bib103","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/j.1572-0241.2006.00661.x","article-title":"Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial","volume":"101","author":"Spechler","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib104","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1365-2036.2005.02432.x","article-title":"Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily\u2013a randomized, two-way crossover study","volume":"21","author":"Miehlke","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib105","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1046\/j.1365-2036.2003.01594.x","article-title":"The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity","volume":"17","author":"Orr","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib106","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1023\/A:1026147126821","article-title":"Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients","volume":"48","author":"Thomson","year":"2003","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2017.09.033_bib107","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.0953-0673.1996.00367.x","article-title":"The effects of omeprazole 20 and 40 mg twice daily on intragastric acidity in duodenal ulcer patients","volume":"10","author":"Savarino","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib108","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/j.1365-2036.2005.02513.x","article-title":"Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease","volume":"21","author":"Castell","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib109","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1046\/j.1365-2036.1999.00587.x","article-title":"Post-prandial ranitidine is superior to post-prandial omeprazole in control of gastric acidity in healthy volunteers","volume":"13","author":"Khoury","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib110","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-2036.2000.00775.x","article-title":"Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole","volume":"14","author":"Katz","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib111","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2036.2004.02079.x","article-title":"Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study","volume":"20","author":"Katz","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib112","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2036.1992.tb00057.x","article-title":"The effects of lansoprazole, a new H+,K(+)-ATPase inhibitor, on gastric pH and serum gastrin","volume":"6","author":"Sanders","year":"1992","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib113","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1046\/j.1365-2036.1997.00195.x","article-title":"Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole\u2013comparison of 24-hour intragastric and oesophageal pH","volume":"11","author":"Armbrecht","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib114","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00004836-199703000-00003","article-title":"The effects of oral doses of lansoprazole and omeprazole on gastric pH","volume":"24","author":"Tolman","year":"1997","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib115","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2036.2001.00967.x","article-title":"Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg","volume":"15","author":"Katz","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib116","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2036.1992.tb00550.x","article-title":"Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration","volume":"6","author":"Chiverton","year":"1992","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib117","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0016-5085(85)80133-5","article-title":"Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage","volume":"88","author":"Prichard","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2017.09.033_bib118","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1046\/j.1365-2036.2000.00772.x","article-title":"A\u00a0placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects","volume":"14","author":"Williams","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib119","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1046\/j.1365-2036.2000.00774.x","article-title":"Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection","volume":"14","author":"Ohning","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1185\/03007995.2014.980500","article-title":"Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: a post hoc analysis of the LOTUS trial","volume":"31","author":"Lundell","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cgh.2017.09.033_bib121","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/gut.31.5.509","article-title":"Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring","volume":"31","author":"Dehn","year":"1990","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2017.09.033_bib122","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2009.556","article-title":"Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system","volume":"105","author":"Vasiliadis","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib123","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1046\/j.1365-2036.2001.01030.x","article-title":"Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole","volume":"15","author":"Galmiche","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib124","first-page":"791","article-title":"Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease","volume":"15","author":"Simon","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2017.09.033_bib125","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/00365529850172304","article-title":"Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease","volume":"33","author":"Janczewska","year":"1998","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib126","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/apt.12301","article-title":"Reflux episodes detected by impedance in patients on and off esomeprazole: a randomised double-blinded placebo-controlled crossover study","volume":"37","author":"Moawad","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib127","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1185\/03007990802693883","article-title":"Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials","volume":"25","author":"Vakily","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cgh.2017.09.033_bib128","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1177\/1756283X16670073","article-title":"Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole","volume":"9","author":"Kukulka","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2017.09.033_bib129","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/j.1365-2036.2010.04272.x","article-title":"The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a dual delayed release proton pump inhibitor","volume":"31","author":"Lee","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2017.09.033_bib130","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356517311680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356517311680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:25:07Z","timestamp":1761542707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356517311680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":130,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1542356517311680"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2017.09.033","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2017.09.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the AGA Institute","name":"copyright","label":"Copyright"}]}}